These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Costs of peripheral blood progenitor cell transplantation using whole blood mobilised by filgrastim as compared with autologous bone marrow transplantation in non-Hodgkin's lymphoma.
    Author: Uyl-de Groot CA, Ossenkoppele GJ, Buijt I, Huijgens PC.
    Journal: Pharmacoeconomics; 1999 Mar; 15(3):305-11. PubMed ID: 10537437.
    Abstract:
    OBJECTIVE: The aim of this paper is to compare the costs of autologous bone marrow transplantation (ABMT) and whole blood transplantation in patients with relapsed or poorly responding non-Hodgkin's lymphoma. DESIGN AND SETTING: In a retrospective study, we calculated the treatment costs of 40 patients who received either ABMT or, alternatively, whole blood mobilised by filgrastim (a granulocyte colony-stimulating factor. MAIN OUTCOME MEASURES AND RESULTS: The recovery of granulocytes was markedly accelerated in the whole blood group as compared with the ABMT group. This resulted in a reduction in hospital costs, and costs for diagnostics and medical procedures, antibacterials, nutrition and blood transfusions. The average costs per patient in the whole blood group amounted to approximately $US16,890 as compared with approximately $US20,713 in the ABMT group (1995 values), implying a cost reduction of 18% when changing to whole blood reinfusion. CONCLUSIONS: With the premise that both therapies are equivalent, it seems that whole blood transplantation is more cost effective than ABMT.
    [Abstract] [Full Text] [Related] [New Search]